Tomahawk, WI 06/18/2014 (Basicsmedia) – Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)’s new success story emerged as a bane for investments, presumably!
Lymphoseek Gets FDA’s Nod
On June 13, NAVB announced that the US FDA have approved the rampant use of Lymphoseek injection (Technetium 99m tilmanocept) for supplemental New-Drug Application (or sNDA). This new drug is an exquisite radioactive diagnostic-imaging agent that helps doctors determine the type of squamous cell carcinoma and the extent to which it spread across a user’s head or neck regions.
Lymphoseek was approved for the first time in March 2013, for due lymphatic mapping for melanoma and breast cancer patients. It is the sole FDA-approved application of radio-pharmaceuticals for sentinel lymph-node biopsy.
Estimated Impact Of Lymphoseek
Stephen Y. Lai, an emeritus professor at the University of Texas stated that at the current healthcare standards in the US, tumors or lymph nodes in numbers of 30 or more can be removed by surgical processes. He further added that at this juncture, the inception of Lymphoseek might be effective in precise SLN mapping and suitably decreasing nodal excision, lowering merely to four lymph nodes. Indeed, Lymphoseek offers effective post-surgical treatments, decreasing patient morbidity.
Better Treatment At Lower Prices
Various NGOs and Cancer foundations have welcomed the diagnostic advancement proclaimed by Lymphoseek and its latest approval by the FDA, that ensures less-invasive procedures for patients suffering from oral, neck or head cancers. The NAVB Interim CEO, Michael Goldberg commented that the approval of Lymphoseek by FDA would evolve as a respite for a number of cancer patients, not only playing a pivotal role in treating cancers holistically, but also curbing costs and ushering savings significantly.
The acceptance of Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)’s Lymphoseek among enumerable fraternities and the plenitude of positive reviews that the diagnostic radio-pharmaceutical drug has already notched up, corroborates that Lymphoseek will find many takers and should play a pivotal role in diminishing the obfuscation of head or neck cancers, ensuring better treatment at lower costs.
However, despite a clinical innovation that is expected to bolster Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)’s market gains and help it tread with a stronger foothold in the near future, the investors have acted otherwise! Perhaps, the dwindling prices, amidst voluminous trade activity, reveal that the investors are concerned about longstanding profits. Prices are deemed to soar up once the investors are re-affirmed that the company can assume sumptuous profitability in FY 2014-15.